Vanguard Group Inc. Boosts Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Vanguard Group Inc. grew its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 10.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,922,662 shares of the company's stock after acquiring an additional 180,325 shares during the period. Vanguard Group Inc. owned 3.36% of Phathom Pharmaceuticals worth $19,938,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Invesco Ltd. grew its position in Phathom Pharmaceuticals by 2.6% in the third quarter. Invesco Ltd. now owns 3,418,959 shares of the company's stock worth $35,455,000 after acquiring an additional 86,822 shares in the last quarter. Algert Global LLC bought a new stake in shares of Phathom Pharmaceuticals during the 3rd quarter worth $952,000. Wellington Management Group LLP boosted its holdings in shares of Phathom Pharmaceuticals by 1.8% during the 3rd quarter. Wellington Management Group LLP now owns 99,810 shares of the company's stock worth $1,035,000 after buying an additional 1,797 shares during the period. GSA Capital Partners LLP boosted its holdings in shares of Phathom Pharmaceuticals by 126.1% during the 3rd quarter. GSA Capital Partners LLP now owns 121,892 shares of the company's stock worth $1,264,000 after buying an additional 67,983 shares during the period. Finally, Trexquant Investment LP boosted its holdings in shares of Phathom Pharmaceuticals by 221.4% during the 3rd quarter. Trexquant Investment LP now owns 58,825 shares of the company's stock worth $610,000 after buying an additional 40,524 shares during the period. 99.01% of the stock is owned by institutional investors.

Phathom Pharmaceuticals Stock Down 1.2 %

Phathom Pharmaceuticals stock traded down $0.12 during midday trading on Monday, hitting $10.02. 597,330 shares of the stock were exchanged, compared to its average volume of 867,406. The company has a fifty day simple moving average of $9.38 and a two-hundred day simple moving average of $8.75. Phathom Pharmaceuticals, Inc. has a 52 week low of $6.07 and a 52 week high of $17.02. The stock has a market capitalization of $585.97 million, a PE ratio of -2.57 and a beta of 0.63.

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.12. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.93 million. During the same period in the previous year, the firm posted ($1.33) EPS. As a group, equities research analysts anticipate that Phathom Pharmaceuticals, Inc. will post -4.22 EPS for the current fiscal year.

Insider Buying and Selling at Phathom Pharmaceuticals

In other Phathom Pharmaceuticals news, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $8.10, for a total transaction of $29,999,994.30. Following the sale, the insider now directly owns 3,755,583 shares in the company, valued at $30,420,222.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Phathom Pharmaceuticals news, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $8.10, for a total transaction of $29,999,994.30. Following the completion of the sale, the insider now owns 3,755,583 shares of the company's stock, valued at approximately $30,420,222.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Molly Henderson sold 6,307 shares of the firm's stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $7.75, for a total transaction of $48,879.25. Following the sale, the chief financial officer now directly owns 98,698 shares of the company's stock, valued at approximately $764,909.50. The disclosure for this sale can be found here. Insiders have sold a total of 3,730,296 shares of company stock worth $30,240,515 over the last ninety days. Insiders own 7.50% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a "buy" rating and issued a $26.00 price target on shares of Phathom Pharmaceuticals in a report on Thursday.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.